Compare KKR & Co Inc (KKR) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
KKR & Co Inc vs Vertex Pharmaceuticals Incorporated — how do they compare? KKR & Co Inc trades at $110 (market cap $99.61B), while Vertex Pharmaceuticals Incorporated trades at $528.63 (market cap $134.25B). The key difference: Vertex Pharmaceuticals Incorporated is the larger of the two by market cap, and KKR & Co Inc pays a 0.7% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals.
| KKR | VRTX | |
|---|---|---|
Market Cap | $99.61B | $134.25B |
Sector | Financials | Health |
52-Week High | $149.34 | $529.65 |
52-Week Low | $83.88 | $376.62 |
Enterprise Value | $22.17B | $128.37B |
Dividend Yield | 0.7% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
KKR trades at $103.83, up 0.99% with strong bullish momentum. The stock shows robust earnings performance with Q2 2026 EPS of $1.63 beating estimates of $1.43, continuing a trend of positive surprises. Recent acquisitions including Integer Holdings ($4.3B) and Medicover India ($1.39B) demonstrate aggressive growth strategy. Analyst consensus remains overwhelmingly bullish with 24 buy ratings and $127.22 price target, representing 22.5% upside potential from current levels.
KKR presents compelling investment opportunity with strong fundamentals, consistent earnings beats, and strategic acquisitions driving growth. Key risks include integration challenges from recent deals, market volatility affecting asset management fees, and potential regulatory scrutiny of private equity operations. The company's $19.2B infrastructure fund closure signals strong institutional confidence in long-term strategy.
Vertex Pharmaceuticals (VRTX) trades at $523.91, up 5.61% with strong technical momentum and bullish moving averages. The company reported Q2 2026 revenue growth of 12% to $3.3 billion, beating expectations despite an EPS miss, and raised its full-year 2026 revenue guidance. Valuation metrics show a P/E of 30.85 and P/S of 10.78, while maintaining robust profitability with 86% gross margins and 35% net income margins.
Outlook remains positive with analyst consensus strongly bullish (84% buy ratings) and a $534.25 price target. Key risks include execution on newer product launches and competitive pressures in cystic fibrosis treatments. The stock's current momentum suggests continued upside potential, though RSI levels indicate potential near-term overbought conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About KKR & Co Inc
KKR is one of the world's largest alternative asset managers, with $490.7 billion in total assets under management, including $384.5 billion in fee-earning AUM, at the end of June 2022. The company has two core segments: asset management (which includes private markets--private equity, credit, infrastructure, energy and real estate--and public markets--primarily credit and hedge/investment fund platforms) and insurance (following the February 2021 purchase of a 61.5% economic stake in Global Atlantic Financial Group, which is engaged in retirement/annuity and life insurance lines as well as reinsurance). On the asset management side, private markets account for 50% of fee-earning AUM and 70% of base management fees, while public markets account for 50% and 30%, respectively.
Read more on KKR →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
